Pharmafile Logo

Glaucoma in perspective

- PMLiVE

Almirall and Inserm Transfert to develop innovative vitiligo treatments

Vitiligo is a chronic skin condition that affects patients worldwide

- PMLiVE

Recognising HIV Vaccine Awareness Day

HIV Vaccine Awareness Day is on 18 May

- PMLiVE

AstraZeneca and UK-based biotech company RQ BIO sign licencing agreement

RQ BIO has developed a portfolio of early-stage monoclonal antibodies targeting SARS-CoV-2

- PMLiVE

Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data

The potential new oral treatment showed a reduction in lung function decline

- PMLiVE

NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer

The treatment will be available for eligible patients in England with a stage 3 diagnosis

- PMLiVE

Phase 3 trial of AstraZeneca and Avillion’s PT027 shows promise for asthma patients

Results of MANDALA trial will be presented at the American Thoracic Society (ATS) 2022 International Conference

- PMLiVE

MHRA approves Infex Therapeutics’s study for treatment for non-cystic fibrosis patients

The treatment, for Pseudomonas aeruginosa, will address a chronic and debilitating respiratory condition that has no approved available treatments

- PMLiVE

Shionogi and F2G partner to develop antifungal treatment olorofim

The deal, worth up to $480m, involves the first novel antifungal treatment developed in the last 20 years

- PMLiVE

Holistic Excellence

Why is it so hard to make your team or company excellent? Ask your Jeremiah

- PMLiVE

Bristol Myers Squibb releases positive trial results for plaque psoriasis treatment

Plaque psoriasis is a chronic, systemic immune-mediated disease associated with multiple serious comorbidities

- PMLiVE

Scientists discover new approach to treat brain tumours

The results from the University of Surrey are from a seven-year research study on glioblastoma multiforme

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links